HPR52 TNF-Alfa Inhibitor Therapies: Evaluating the Impact of Biosimilars Competition in Italy, Portugal and Spain
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.1184
https://www.valueinhealthjournal.com/article/S1098-3015(22)03389-7/fulltext
Title :
HPR52 TNF-Alfa Inhibitor Therapies: Evaluating the Impact of Biosimilars Competition in Italy, Portugal and Spain
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03389-7&doi=10.1016/j.jval.2022.09.1184
First page :
Section Title :
Open access? :
No
Section Order :
10734